Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 556
Filtrar
1.
Trop Biomed ; 38(3): 435-445, 2021 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-34608117

RESUMEN

Ever since the first reported case series on SARS-CoV-2-induced neurological manifestation in Wuhan, China in April 2020, various studies reporting similar as well as diverse symptoms of COVID-19 infection relating to the nervous system were published. Since then, scientists started to uncover the mechanism as well as pathophysiological impacts it has on the current understanding of the disease. SARS-CoV-2 binds to the ACE2 receptor which is present in certain parts of the body which are responsible for regulating blood pressure and inflammation in a healthy system. Presence of the receptor in the nasal and oral cavity, brain, and blood allows entry of the virus into the body and cause neurological complications. The peripheral and central nervous system could also be invaded directly in the neurogenic or hematogenous pathways, or indirectly through overstimulation of the immune system by cytokines which may lead to autoimmune diseases. Other neurological implications such as hypoxia, anosmia, dysgeusia, meningitis, encephalitis, and seizures are important symptoms presented clinically in COVID-19 patients with or without the common symptoms of the disease. Further, patients with higher severity of the SARS-CoV-2 infection are also at risk of retaining some neurological complications in the long-run. Treatment of such severe hyperinflammatory conditions will also be discussed, as well as the risks they may pose to the progression of the disease. For this review, articles pertaining information on the neurological manifestation of SARS-CoV-2 infection were gathered from PubMed and Google Scholar using the search keywords "SARS-CoV-2", "COVID-19", and "neurological dysfunction". The findings of the search were filtered, and relevant information were included.


Asunto(s)
COVID-19/patología , Sistema Nervioso Central/patología , Enfermedades del Sistema Nervioso/virología , Sistema Nervioso Periférico/patología , Enzima Convertidora de Angiotensina 2/metabolismo , Anosmia/virología , Sistema Nervioso Central/virología , Disgeusia/virología , Encefalitis Viral/virología , Humanos , Meningitis Viral/virología , Enfermedades del Sistema Nervioso/patología , Sistema Nervioso Periférico/virología , SARS-CoV-2 , Convulsiones/virología
2.
Pediatr Dent ; 43(4): 282-284, 2021 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-34467844

RESUMEN

Purpose: An altered sense of taste (dysgeusia) has been associated with COVID-19 infection in adults but is not sufficiently documented in children. The purpose of this study was to assess the odds ratio for dysgeusia associated with COVID-19 in a pediatric population of a major health center. Methods: Deidentified aggregate data, provided by the chief data officer (Informatics for Integrating Biology and the Bedside-I2B2) from June 2015 to October 2020, was used for correlation using the dysgeusia code (ICD 10 R43.2) with and without positivity for COVID-19. COVID-19 patients were measured from January 2020 to October 2020. Results: Among the 552 children who tested positive for COVID-19, nine also tested positive for dysgeusia and were older than nine years of age (odds ratio equals 149.5; 95 percent confidence interval equals 66.9 to 334.3; P<0.001). Conclusions: Based on a strong association between COVID-19 and dysgeusia in children, dental professionals treating children are recommended to include questions about recent changes in appetite and taste as part of their patient screening COVID-19 questionnaire.


Asunto(s)
COVID-19 , Trastornos del Olfato , Adulto , Niño , Disgeusia/epidemiología , Disgeusia/etiología , Humanos , Prevalencia , SARS-CoV-2
3.
Laryngorhinootologie ; 100(8): 600-601, 2021 08.
Artículo en Alemán | MEDLINE | ID: mdl-34320671
4.
Laryngorhinootologie ; 100(8): 601, 2021 08.
Artículo en Alemán | MEDLINE | ID: mdl-34320672

Asunto(s)
Disgeusia , Fumar , Humanos
5.
Intern Med ; 60(18): 2905-2910, 2021 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-34248118

RESUMEN

Objective Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), remains the world's largest public health concern in 2021. A history of close contact with infectious patients is a factor that predicts a positive SARS-CoV-2 test result. Meanwhile, the precise predictive value of symptoms suggestive of COVID-19 has not been fully elucidated. This study aimed to clarify the predictive and discriminatory value of each clinical symptom suggestive of COVID-19. Methods This study enrolled participants who were tested for SARS-CoV-2 by reverse transcription polymerase chain reaction using a nasopharyngeal swab between November 2020 and January 2021. All enrolled patients were evaluated for data regarding the presence and closeness of contact with infectious patients and comprehensive clinical features (i.e., fever, cough, dyspnea, fatigue, dysosmia, and dysgeusia). Results Among the 1,744 tested participants, 144 tested positive for SARS-CoV-2. In the test-positive group, self-reported cough, fatigue, dysosmia, and dysgeusia were significant predictors of COVID-19, independent from a history of close contact. In particular, the presence of dysosmia was the strongest predictor of COVID-19 in both univariate and multivariate analyses. Among the 42 patients with self-reported dysosmia, 25 (59.5%) were SARS-CoV-2 test-positive. Self-reported dysosmia was reported by 25 (17.4%) of the 144 patients who tested positive for SARS-CoV-2, and 15 (60.0%) of the 25 COVID-19 patients with dysosmia had accompanying dysgeusia. Conclusion The presence of dysosmia was reported by 10-25% of patients with COVID-19, and is a significant predictor of COVID-19 infection, independent from a history of close contact.


Asunto(s)
COVID-19 , Trastornos del Olfato , Disgeusia , Humanos , SARS-CoV-2 , Autoinforme
6.
Acta Biomed ; 92(S2): e2021023, 2021 07 29.
Artículo en Inglés | MEDLINE | ID: mdl-34328144

RESUMEN

BACKGROUND AND AIM: Dysgeusia is  an altered or damaged tasting perception of a multifactorial etiology, from polypharmacy, infections to chemotherapy and radiotherapy. Approximately 5% of the population suffer from a diminished taste sensation, which unfortunately remains underestimated by the affected person, creating the conditions for a dramatic underestimation of the incidence of the symptom. The aim of this study is to summarize the evidences present in literature on the relations between Dysgeusia and alterations of the nutritional status Methods: an integrative review with metanarrative analysis of the articles included was carried out in August 2020. PubMed, Scopus, Embase and CINAHL databases were examined with keywords and methodological strings. PRISMA flow-chart along with a qualitative evaluation grid (JBI-QARI) were applied in the selection of the studies with a time limitation to the last ten years. RESULTS: 10 articles resulted from the literature review process were divided into two macro-categories. Eight articles reported dysgeusia linked to weight loss. The second macro-category showed two studies relating to dysgeusia in patients with altered nutritional status associated with body weight gain. CONCLUSIONS: this review represents an initial contribution to summarize the best evidence and knowledge in relation to dysgeusia, with the aim of enabling the identification and treatment of this symptom and facilitating targeted educational interventions.


Asunto(s)
Disgeusia , Estado Nutricional , Disgeusia/etiología , Humanos , Polifarmacia , Pérdida de Peso
8.
Rev. cient. odontol ; 9(2): e057, abr.-jun. 2021. tab
Artículo en Español | LILACS, LIPECS | ID: biblio-1254596

RESUMEN

Objetivo: Determinar la prevalencia de trastornos del gusto en pacientes niños y adolescentes diagnosticados con infección por coronavirus, a través de la evidencia en la literatura científica. Materiales y métodos: Una revisión sistemática de los artículos publicados entre el 19 de diciembre del 2019 y el 20 de diciembre del 2020 en las bases de datos Medline, Lilacs, BVS, Cochrane, SCOPUS y ScienceDirect. La estrategia de búsqueda de información se basó en el diagrama de flujo clásico de PRISMA. Para la evaluación del riesgo de sesgo, se usó la escala Newcastle-Ottawa. Resultados: Se encontraron 443 artículos en seis bases de datos y se incluyó un total de 7 artículos después de la evaluación, según los criterios de selección. Los artículos abordaron la variable de trastornos del gusto en tres formas: ageusia, disgeusia e hipogeusia, y se halló que esta manifestación clínica estaba presente desde los inicios de la infección. Conclusiones: Se ha encontrado una prevalencia de trastornos del gusto en niños y adolescentes diagnosticados con infección por coronavirus desde un 3,3% hasta un 26,9%. (AU)


Aim: To assess the prevalence of taste disorders in children and adolescents diagnosed with coronavirus infection according to the evidence reported in the scientific literature. Materials and Methods: A systematic review of articles published between December 19, 2019, and December 20, 2020 in the Medline, Lilacs, BVS, Cochrane, SCOPUS and ScienceDirect databases. The information search strategy was based on the classic PRISMA flow diagram. The Newcastle-Ottawa scale was used to assess the risk of bias. Results: 443 articles were found in six databases, and a total of 7 articles were included after evaluation according to the selection criteria. The articles addressed the variable of taste disorders in three ways: ageusia, dysgeusia and hypogeusia; finding that this clinical manifestation was present from the beginning of the infection. Conclusions: The prevalence of taste disorders in children and adolescents diagnosed with coronavirus infection is from 3.3% to 26.9%. (AU)


Asunto(s)
Humanos , Masculino , Femenino , Niño , Adolescente , Trastornos del Gusto , Infecciones por Coronavirus , Ageusia , Disgeusia
9.
Eur J Oncol Nurs ; 52: 101956, 2021 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-33940487

RESUMEN

PURPOSE: This study evaluates the effect of a self-monitoring intervention on taste alterations in breast cancer patients undergoing outpatient chemotherapy. METHODS: The study was a randomized controlled trial. Thirty-four participants were divided into two groups: a self-monitoring (SMG) group (n = 17) and a control group (CG) (n = 17). A conceptual framework was developed with reference to the components of self-management, cognitive behavioral therapy, and the concepts of self-monitoring. Interventions were based on this framework. SMGs recorded their taste symptoms as homework and worked with the researcher to set goals and provide feedback four times every three weeks. In the feedback, the researcher actively listened to the SMG about their feelings and coping strategies during the taste changes, and gave approval and praise for these. The implementation period was 9 weeks for each participant; the CG was provided with conventional nursing support. The intervention was evaluated by comparing the items of symptom improvement, quality of life (QOL), and self-efficacy between the groups before and after the start of the intervention using a scale score. Scale scores were also compared for recognition of taste changes, concerns during treatment, distress, and impacts on each treatment day. RESULTS: SMG had significantly lower scores than CG for perceived change in taste (p = 0.009), and there was an interaction with CG (p = 0.008). SMG had also significantly lower scores than CG in concern during treatment (p = 0.015). CONCLUSION: This study showed that a self-monitoring intervention reduced negative cognition of taste alterations and reduced discomfort. The results suggest that the self-monitoring intervention is effective nursing support for chemotherapy-induced taste alterations.


Asunto(s)
Neoplasias de la Mama , Automanejo , Neoplasias de la Mama/tratamiento farmacológico , Disgeusia , Femenino , Humanos , Calidad de Vida , Gusto
10.
Clin Nutr ESPEN ; 43: 532-535, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-34024566

RESUMEN

BACKGROUND & AIMS: The symptoms of xerostomia and taste alteration are adverse effects which frequently occur in patients under chemotherapy and once associated they can potentially impair their nutritional status. The aim of this study was to investigate the association of xerostomia and taste alterations in patients being treated by neoplastic chemotherapy. METHODS: Fifty patients scheduled to receive neoplastic chemotherapy were followed for their first two chemotherapy cycles for solid tumors and the Chemotherapy-Induced Taste Alteration Scale (CiTAS) was adopted. Xerostomia was defined by the presence of dry mouth complaints reported by the patients and signs of hyposalivation identified during the intraoral examination. RESULTS: Of the 50 patients, 33 were women, mean age; 61,48 ± 9,07 years, and 17 were men, mean age; 57,35 ± 11,50 years. The most common tumor was located in the breast affecting 15 patients (30%). The Mann-Whitney test showed that the mean scores of CiTAS were significantly higher for those patients who reported having xerostomia when compared with those without xerostomia after the first two chemotherapy cycles. The cofounding variables such as age, smoking habits and use of antidepressants were not statistically associated with taste alterations (p > 0.05). CONCLUSIONS: Taste alterations were worse for patients who complained of xerostomia during the first two cycles of antineoplastic chemotherapy and the association of both symptoms can potentially impair their nutritional status and quality of life.


Asunto(s)
Antineoplásicos , Xerostomía , Antineoplásicos/efectos adversos , Disgeusia/inducido químicamente , Disgeusia/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Gusto , Xerostomía/inducido químicamente , Xerostomía/epidemiología
11.
Eur Rev Med Pharmacol Sci ; 25(8): 3350-3364, 2021 04.
Artículo en Inglés | MEDLINE | ID: mdl-33928623

RESUMEN

OBJECTIVE: The purpose of this article was to review our clinical experience with COVID-19 patients observed in the Cardiovascular Division of Pompidou Hospital (University of Paris, France) and the Department of Neurology of the Eastern Piedmont University (Novara, Italy), related to the impact on the cardiovascular, hematological, and neurologic systems and sense organs. PATIENTS AND METHODS: We sought to characterize cardiovascular, hematological, and neurosensory manifestations in patients with COVID-19 and variants. Special attention was given to initial signs and symptoms to facilitate early diagnosis and therapy. Indications of ECMO (extracorporeal membrane oxygenation) for cardiorespiratory support were evaluated. RESULTS: Preliminary neurosensorial symptoms, such as anosmia and dysgeusia, are useful for diagnosis, patient isolation, and treatment. Early angiohematological acro-ischemic syndrome includes hand and foot cyanosis, Raynaud digital ischemia phenomenon, skin bullae, and dry gangrene. This was associated with neoangiogenesis, vasculitis, and vessel thrombosis related to immune dysregulation, resulting from "cytokine storm syndrome". The most dangerous complication is disseminated intravascular coagulation, with mortality risks for both children and adults. CONCLUSIONS: COVID-19 is a prothrombotic disease with unique global lethality. A strong inflammatory response to viral infection severely affects cardiovascular and neurological systems, as well as respiratory, immune, and hematological systems. Rapid identification of acro-ischemic syndrome permits the treatment of disseminated intravascular coagulation complications. Early sensorial symptoms, such as gustatory and olfactory loss, are useful for COVID-19 diagnosis. New variants of SARS-CoV-2 are emerging, principally from United Kingdom, South Africa, and Brazil. These variants seem to spread more easily and quickly, which may lead to more cases of COVID.


Asunto(s)
Anosmia/fisiopatología , COVID-19/fisiopatología , Cianosis/fisiopatología , Coagulación Intravascular Diseminada/fisiopatología , Disgeusia/fisiopatología , Miocarditis/fisiopatología , Enfermedad de Raynaud/fisiopatología , Vasculitis/fisiopatología , COVID-19/patología , COVID-19/terapia , COVID-19/virología , Proteasas 3C de Coronavirus/ultraestructura , Síndrome de Liberación de Citoquinas , Coagulación Intravascular Diseminada/patología , Oxigenación por Membrana Extracorpórea , Pie/irrigación sanguínea , Francia , Gangrena/patología , Gangrena/fisiopatología , Mano/irrigación sanguínea , Humanos , Isquemia/patología , Isquemia/fisiopatología , Ventilación no Invasiva , Intercambio Plasmático , Enfermedad de Raynaud/patología , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus/ultraestructura , Sincrotrones , Vasculitis/patología
12.
F1000Res ; 10: 40, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33824716

RESUMEN

Background: The present study aimed to determine the global prevalence of anosmia and dysgeusia in coronavirus disease 2019 (COVID-19) patients and to assess their association with severity and mortality of COVID-19. Moreover, this study aimed to discuss the possible pathobiological mechanisms of anosmia and dysgeusia in COVID-19. Methods: Available articles from PubMed, Scopus, Web of Science, and preprint databases (MedRxiv, BioRxiv, and Researchsquare) were searched on November 10th, 2020. Data on the characteristics of the study (anosmia, dysgeusia, and COVID-19) were extracted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Newcastle-Ottawa scale was used to assess research quality. Moreover, the pooled prevalence of anosmia and dysgeusia were calculated, and the association between anosmia and dysgeusia in presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was assessed using the Z test. Results: Out of 32,142 COVID-19 patients from 107 studies, anosmia was reported in 12,038 patients with a prevalence of 38.2% (95% CI: 36.5%, 47.2%); whereas, dysgeusia was reported in 11,337 patients out of 30,901 COVID-19 patients from 101 studies, with prevalence of 36.6% (95% CI: 35.2%, 45.2%), worldwide. Furthermore, the prevalence of anosmia was 10.2-fold higher (OR: 10.21; 95% CI: 6.53, 15.96, p < 0.001) and that of dysgeusia was 8.6-fold higher (OR: 8.61; 95% CI: 5.26, 14.11, p < 0.001) in COVID-19 patients compared to those with other respiratory infections or COVID-19 like illness. To date, no study has assessed the association of anosmia and dysgeusia with severity and mortality of COVID-19. Conclusion: Anosmia and dysgeusia are prevalent in COVID-19 patients compared to those with the other non-COVID-19 respiratory infections. Several possible mechanisms have been hypothesized; however, future studies are warranted to elucidate the definitive mechanisms of anosmia and dysgeusia in COVID-19. Protocol registration: PROSPERO CRD42020223204.


Asunto(s)
Anosmia/virología , COVID-19/complicaciones , Disgeusia/virología , Humanos , Incidencia
13.
Neuroepidemiology ; 55(2): 154-161, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33794531

RESUMEN

INTRODUCTION: Smell and taste loss are characteristic symptoms of SARS-CoV-2 infection. The aim of this study is to investigate the prevalence and risk factors associated with olfactory and gustatory dysfunctions in coronavirus disease (COVID-19) patients. METHODS: We conducted an observational, retrospective study on 376 patients with documented SARS-CoV-2 infection admitted to the San Gerardo Hospital in Monza, Italy, from March to July 2020. All patients answered a phone questionnaire providing information on age, sex, smoking status, and clinical characteristics. Adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were estimated through logistic regression models including relevant covariates. RESULTS: The prevalence of olfactory and gustatory dysfunctions in COVID-19 patients was 33.5 and 35.6%, respectively. Olfactory dysfunctions were significantly directly associated with current smoking and history of allergy, the multivariable ORs being 6.53 (95% CI 1.16-36.86) for current smokers versus never smokers, and 1.89 (95% CI 1.05-3.39) for those with an allergy compared to those without any allergy. Respiratory allergy in particular was significantly associated with olfactory dysfunctions (multivariable OR 2.30, 95% CI 1.02-5.17). Significant inverse associations were observed for patients aged 60 years or more (multivariable OR 0.33, 95% CI 0.19-0.57) and hospitalization (multivariable OR 0.22, 95% CI 0.06-0.89). Considering gustatory dysfunctions, after allowance of other variables a significant direct association was found for respiratory allergies (OR 2.24, 95% CI 1.03-4.86), and an inverse association was found only for hospitalization (OR 0.21, 95% CI 0.06-0.76). CONCLUSION: Our study indicates that current smoking and history of allergy (particularly respiratory) significantly increase the risk for smell loss in COVID-19 patients; the latter is also significantly associated to taste loss. Hospitalization has an inverse association with the risk of olfactory and gustatory dysfunctions, suggesting that these may be symptoms characteristics of less severe SARS-CoV-2 infection.


Asunto(s)
Anosmia/epidemiología , COVID-19/fisiopatología , Disgeusia/epidemiología , Hipersensibilidad Respiratoria/epidemiología , Fumar/epidemiología , Factores de Edad , Anciano , Anosmia/fisiopatología , Disgeusia/fisiopatología , Servicio de Urgencia en Hospital , Femenino , Hospitalización , Humanos , Hipersensibilidad/epidemiología , Modelos Logísticos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Trastornos del Olfato/epidemiología , Trastornos del Olfato/fisiopatología , Prevalencia , Estudios Retrospectivos , Factores de Riesgo , SARS-CoV-2 , Trastornos del Gusto/epidemiología , Trastornos del Gusto/fisiopatología
14.
Head Neck ; 43(7): 2159-2177, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33856086

RESUMEN

BACKGROUND: After head and neck cancer (HNC) treatment, dysgeusia may be a barrier to oral intake. In this exploratory study, we prospectively examined taste perception, clinician-rated (CRO) and patient-reported (PRO) taste changes and their effect on oral intake postradiotherapy. METHODS: Twenty-eight patients were assessed at baseline, treatment weeks 2 and 4, and 1, 3, and 6 months post-treatment using a whole-mouth taste test and associated CRO and subjective PRO measures. RESULTS: Greater taste impairment was reflected by subjective than by a whole-mouth taste test. The most significant and consistent decline occurred mid-treatment. The Chemotherapy-Induced Taste Alteration Scale (PRO) discomfort subscale correlated significantly with maintaining an oral diet, percent of oral intake, and appetite level from mid-treatment to 6 months post-treatment. CONCLUSIONS: PRO results indicated ongoing oral intake issues. Whole-mouth taste tests may fail to fully reflect functional taste-loss. Dysgeusia prevention and treatment methods are needed to improve patient outcomes.


Asunto(s)
Disgeusia , Neoplasias de Cabeza y Cuello , Disgeusia/diagnóstico , Disgeusia/etiología , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Boca , Medición de Resultados Informados por el Paciente , Gusto
17.
J Dent Res ; 100(7): 754-763, 2021 07.
Artículo en Inglés | MEDLINE | ID: mdl-33703950

RESUMEN

Oral mucositis and taste dysfunction are frequently complained by patients with head and neck cancer receiving radiotherapy, challenging the clinical outcome of cancer treatment. Recent studies have indicated the protective role of Wnt/ß-catenin signaling in radiation-induced oral mucositis (RIOM) and its pivotal role in the development and self-renewal of taste buds. The current study hypothesizes that lithium chloride (LiCl), a potent activator of the Wnt/ß-catenin signaling pathway, can promote the postirradiation restoration of oral mucosa integrity and taste function. To validate this hypothesis, we established a RIOM mouse model and evaluated the treatment efficacy of LiCl on oral mucositis and taste dysfunction in comparison with keratinocyte growth factor (KGF), an agent approved by the US Food and Drug Administration for oral mucositis. The results showed that LiCl alleviated the weight loss and tongue ulceration of RIOM mice, promoted proliferation of basal epithelial cells, and inhibited epithelial-mesenchymal transition in tongue mucosa. More important, elevated taste bud renewal and dysgeusia recovery toward sweetness were observed in RIOM mice treated with LiCl as compared to those treated by KGF. Collectively, our data demonstrate that LiCl can mitigate oral mucositis and rescue taste alteration induced by irradiation, and activation of Wnt/ß-catenin signaling may represent a promising therapy to improve the quality of life of patients receiving radiotherapy.


Asunto(s)
Cloruro de Litio , Estomatitis , Animales , Disgeusia , Humanos , Ratones , Calidad de Vida , Estomatitis/tratamiento farmacológico , Estomatitis/etiología , Vía de Señalización Wnt
18.
Cancer Radiother ; 25(5): 507-513, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33685809

RESUMEN

Purpose of this review of medical literature is to present the immediate side effects of radiation therapy for head and neck cancer and their treatment. The likelihood and severity of these immediate side effects depends on a number of factors, including the total dose of radiation delivered, over what time it was delivered and what parts of the head and neck received radiation. Early side effects include: inflammation of the oropharyngeal mucosa (mucositis), painful swallowing (odynophagia), difficulty swallowing (dysphagia), hoarseness, lack of saliva (xerostomia), orofacial pain, laryngeal radionecrosis, dermatitis, hair loss, nausea, vomiting, inadequate nutrition and hydration, and weight loss. These complications can interfere with, and delay treatment. Most of these side effects generally dissipate over time. In conclusion, radiation treatment for the head and neck cancer causes significant early side effects. Many of these side effects present difficult challenges to the patients. Their recognition and treatment can significantly improve the patients' health, long-term survival and quality of life. The review provides information that can assist head and cancer survivors deal with radiation side effects.


Asunto(s)
Neoplasias de Cabeza y Cuello/radioterapia , Radioterapia/efectos adversos , Alopecia/etiología , Encéfalo/efectos de la radiación , Trastornos de Deglución/etiología , Trastornos de Deglución/prevención & control , Deshidratación/etiología , Deshidratación/prevención & control , Disgeusia/etiología , Disgeusia/prevención & control , Dolor Facial/etiología , Dolor Facial/terapia , Fatiga/etiología , Fatiga/prevención & control , Humanos , Cartílagos Laríngeos/patología , Mucosa Bucal/patología , Mucositis/etiología , Mucositis/prevención & control , Náusea/etiología , Náusea/prevención & control , Necrosis/etiología , Necrosis/terapia , Enfermedades Periodontales/etiología , Enfermedades Periodontales/prevención & control , Radiodermatitis/etiología , Radiodermatitis/prevención & control , Vómitos/etiología , Vómitos/prevención & control , Pérdida de Peso , Xerostomía/etiología , Xerostomía/prevención & control
19.
Nutrients ; 13(3)2021 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-33668367

RESUMEN

Differences in sour-taste thresholds have been identified in cognition-related diseases. Diet is a modulator of cognitive health, and taste perception influences dietary preferences and habits. Heritable genetics and polymorphisms in the KCNJ2 gene involved in the transduction of sour taste have been linked to variations in sour taste and non-gustatory functions. However, relationships between sour taste genetics, mild cognitive impairment, and diet quality are yet to be elucidated. This study investigated the associations between the presence of the KCNJ2-rs236514 variant (A) allele, diet quality indices, and mild cognitive impairment evaluated by the Mini-Mental State Examination (MMSE), in a secondary cross-sectional analysis of data from the Retirement Health & Lifestyle Study. Data from 524 elderly Australians (≥65y) were analyzed, using standard least squares regression and nominal logistic regression modeling, with demographic adjustments applied. Results showed that the presence of the KCNJ2-A allele is associated with increased proportions of participants scoring in the range indicative of mild or more severe cognitive impairment (MMSE score of ≤26) in the total cohort, and males. These associations remained statistically significant after adjusting for age, sex, and diet quality indices. The absence of association between the KCNJ2-A allele and cognitive impairment in women may be related to their higher diet quality scores in all indices. The potential link between sour taste genotype and cognitive impairment scores may be due to both oral and extra-oral functions of sour taste receptors. Further studies are required on the role and relationship of neurotransmitters, sour taste genotypes and sour taste receptors in the brain, and dietary implications, to identify potential risk groups or avenues for therapeutic or prophylactic interventions.


Asunto(s)
Disfunción Cognitiva/genética , Dieta Saludable/estadística & datos numéricos , Disgeusia/genética , Fenómenos Fisiológicos Nutricionales del Anciano/genética , Canales de Potasio de Rectificación Interna/genética , Anciano , Alelos , Australia , Estudios de Cohortes , Estudios Transversales , Disgeusia/psicología , Femenino , Genotipo , Humanos , Análisis de los Mínimos Cuadrados , Modelos Logísticos , Masculino , Pruebas de Estado Mental y Demencia , Polimorfismo de Nucleótido Simple/genética , Factores Sexuales , Percepción del Gusto/genética , Umbral Gustativo/genética
20.
Rev Neurol ; 72(6): 203-212, 2021 03 16.
Artículo en Inglés, Español | MEDLINE | ID: mdl-33710610

RESUMEN

INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is a major worldwide health disorder. There is an increasing number of neurological complications recognized with COVID-19 including patients with GBS and its variants. DEVELOPMENT: A review of the clinical cases of GBS associated to COVID-19 infection published in the last months has been developed. We included 48 patients (31 men, mean age 56.4 years). The most common COVID-19 symptoms were cough (60.4%) and fever (56.3%). Mean time from COVID-19 symptoms to neurologic manifestations was 12.1 days, but in nine patients (18.8%) developed GBS within seven days. Eleven patients (22.9%) presented cranial nerve involvement in the absence of muscle weakness; 36 presented the classic sensory motor variant (75%) and one had a pure motor variant (2.1%). The electrodiagnostic pattern was considered demyelinating in 82.4% of the generalized variants. The presence of hyposmia/dysgeusia was associated with a latency shorter than seven days to GBS onset of symptoms (30% vs 15.6%), and cranial nerve involvement in the absence of weakness (30.8% vs 17.1%). Most patients (87.5%) were treated with intravenous immunoglobulin. Neurological outcome was favorable in 64.6%; 29.2% had respiratory failure and 4.2% died shortly after being admitted. CONCLUSIONS: GBS in patients with SARS-CoV-2 infection resembles clinically and electrophysiology the classical forms. Further studies are necessary to understand whether GBS frequency is actually increased due to SARS-CoV-2 infection and explore pathogenic mechanisms.


Asunto(s)
COVID-19/complicaciones , Síndrome de Guillain-Barré/etiología , Pandemias , SARS-CoV-2 , Adolescente , Adulto , Anciano , Anosmia/etiología , Autoanticuerpos/sangre , Autoanticuerpos/inmunología , Autoantígenos/inmunología , Enfermedades de los Nervios Craneales/etiología , Disgeusia/etiología , Femenino , Gangliósidos/inmunología , Síndrome de Guillain-Barré/líquido cefalorraquídeo , Síndrome de Guillain-Barré/inmunología , Síndrome de Guillain-Barré/terapia , Humanos , Inmunoglobulinas Intravenosas/uso terapéutico , Masculino , Persona de Mediana Edad , Plasmaféresis , Insuficiencia Respiratoria/etiología , Estudios Retrospectivos , Evaluación de Síntomas , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...